Opportunities within AI and healthcare beyond well-known megacaps
Opportunities within AI and healthcare beyond well-known megacaps
About this video
Sam Ruiz from T Rowe Price shares his views on the current economic landscape. He describes the transition to a clearer and more predictable business environment after a period of unprecedented uncertainty. Businesses now seem able to plan better for factors like inventory and the cost of supply chain shipping. He also talks about investor enquiry, which is now focused more on potential market gains rather than the impending recession.
Sam discusses the usual market heavyweights, The Magnificent Seven, highlighting divergence in their performance. He discussed the need to focus on fundamentals rather than treating them as a collective basket. He mentions specific companies like Nvidia (NVDA), Microsoft (MSFT), and Amazon (AMZN), stating that businesses should be real beneficiaries of generative AI. Regarding AI, Sam discussed separating narrative from price, as he suggests the potential value and significant market growth for generative AI chips.
He also touches on the potential revolution in weight loss with GLP drugs, indicating a significant market opportunity. In the healthcare sector, he highlights the potential of Daiichi Sankyo (TYO: 4568) in Japan, a company engaged in developing tailored cancer treatments, and another company called BE Semiconductor (BESI), which is innovating to increase processing power and data throughput. Sam says his perspective is tied to consistently evaluating the shifting dynamics in a world shaped by AI and technology.